Qube Research & Technologies Ltd grew its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT – Get Rating) by 870.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,486 shares of the company's stock after acquiring an additional 46,182 shares during the quarter. Qube Research & Technologies Ltd owned about 0.10% of Health Catalyst worth $1,345,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently modified their holdings of HCAT. Rhumbline Advisers grew its holdings in Health Catalyst by 0.8% during the fourth quarter. Rhumbline Advisers now owns 49,095 shares of the company's stock worth $1,945,000 after buying an additional 409 shares in the last quarter. State Board of Administration of Florida Retirement System grew its holdings in Health Catalyst by 3.7% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 14,024 shares of the company's stock worth $556,000 after buying an additional 499 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in Health Catalyst by 2.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 22,519 shares of the company's stock worth $892,000 after buying an additional 525 shares in the last quarter. UMB Bank N A MO bought a new stake in Health Catalyst during the fourth quarter worth $30,000. Finally, Fairfield Bush & CO. bought a new stake in Health Catalyst during the first quarter worth $25,000. Institutional investors own 97.53% of the company's stock.
Get Health Catalyst alerts:Analyst Ratings Changes
Several brokerages recently issued reports on HCAT. JPMorgan Chase & Co. downgraded Health Catalyst from an "overweight" rating to a "neutral" rating and decreased their price target for the stock from $20.00 to $16.00 in a report on Friday, August 5th. Piper Sandler cut their price target on Health Catalyst from $38.00 to $21.00 in a research note on Wednesday, May 11th. The Goldman Sachs Group lowered their price objective on Health Catalyst from $29.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday, August 10th. Canaccord Genuity Group cut their target price on shares of Health Catalyst from $35.00 to $17.00 in a research report on Wednesday, May 11th. Finally, Royal Bank of Canada reduced their target price on shares of Health Catalyst from $35.00 to $19.00 in a research note on Wednesday, May 11th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $26.69.
Health Catalyst Price Performance
Shares of Health Catalyst stock opened at $13.54 on Tuesday. Health Catalyst, Inc. has a 1 year low of $10.95 and a 1 year high of $57.19. The firm has a market cap of $740.95 million, a PE ratio of -4.64 and a beta of 1.14. The company has a 50 day simple moving average of $15.02 and a two-hundred day simple moving average of $19.73.Insider Buying and Selling at Health Catalyst
In other news, General Counsel Daniel H. Orenstein sold 2,838 shares of the business's stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $14.85, for a total value of $42,144.30. Following the completion of the sale, the general counsel now directly owns 103,671 shares in the company, valued at approximately $1,539,514.35. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 4,395 shares of company stock worth $64,359 over the last three months. 1.50% of the stock is owned by insiders.
About Health Catalyst
(Get Rating)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights.
Read More
- Get a free copy of the StockNews.com research report on Health Catalyst (HCAT)
- 3 Blowout Earnings Reports That Could Mark Turning Points
- Will CrowdStrike Extend Its Streak Of Topping Earnings Views?
- 3 Stocks Set to Lead the Nasdaq Bull Market
- Skyworks Solutions Is Worth A Look At These Prices
- MarketBeat Podcast: ESG – Profitably Invest Your Values
Want to see what other hedge funds are holding HCAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Health Catalyst, Inc. (NASDAQ:HCAT – Get Rating).
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.